NAS10029,465−1.17%S&P7,723−0.27%GOLD$4,035−0.40%BTC$81,733+0.57%VIX16.46−2.66%latest tape · as of 16:04 UTC
The Screen · Healthcare · Medical Devices
Avanos Medical, Inc.
AVNS · the NYSE · USD · Market cap $1.2B · 2,287 employees
Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price24.99 USD
Fair value14.51
Ethical score70.0/100
Our investment reviews on this name
2026-07-02Read Accumulation24.96+0.1% to today ✓First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Avanos Medical, Inc. holds its Accumulation at $24.99. Consolidating, no directional conviction, held for 20 days.
As held on the ledger · 2026-09-16
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 20 days
Price at the screen
$24.99
Valuation
N/A trailing · 19.99 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.57
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
12.02%
Below 33%
Interest-bearing debt is just 12.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
18.02%
Below 49%
Money owed to the company is 18.0% of assets, under the 49% limit.
Pass
Revenue purity
0.46%
Below 5%
Only 0.5% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Avanos Medical, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 12%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when AVNS's ethical verdict changes
Today AVNS passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-09-16 screen. The gold marker is the market price at the same screen. The price runs 41.9% above the base estimate.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-16 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Feeding tubes sell but profits stay missing
Walk into any hospital ward and you will see enteral feeding tubes keeping patients alive. Avanos makes those tubes yet cannot turn the activity into earnings. The shares trade at twenty-four ninety-seven against our fair value of fourteen fifty-one, a forty-two percent premium that already prices in perfection the business has not delivered.
Revenue edges up nine percent but the bottom line sits at a negative ten percent margin and return on equity is negative nine percent. A forward multiple of twenty times earnings on a loss-making medical device firm leaves no margin of safety. The ethical screen clears, yet the numbers show a company that simply does not compound capital.
High valuation with persistent losses leaves little room for execution slips or reimbursement pressure common in devices. Without a clear moat or path back to solid returns, the setup offers no opportunity worth taking. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
AVNS trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-27Accumulation$24.99+0.0%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 67% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 94%. Our forward projection puts the odds of a 10% gain over the next month near 30%.
2026-10-13Accumulation$24.99+0.0%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 73% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 94%. Our forward projection puts the odds of a 10% gain over the next month near 30%.
2026-10-02Accumulation$24.99+0.0%Entry 7
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 73% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 94%. Our forward projection puts the odds of a 10% gain over the next month near 30%.
2026-09-24Accumulation$24.99+0.0%Entry 6
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 73% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 94%. Our forward projection puts the odds of a 10% gain over the next month near 30%.
2026-08-22Accumulation$24.99+0.1%Entry 5
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 73% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 94%. Our forward projection puts the odds of a 10% gain over the next month near 30%.
2026-07-22Accumulation$24.97+0.0%Entry 4
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 73% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 94%. Our forward projection puts the odds of a 10% gain over the next month near 30%.
2026-07-18Accumulation$24.96+0.0%Entry 3
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 73% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 94%. Our forward projection puts the odds of a 10% gain over the next month near 30%.
2026-07-03Accumulation$24.96+0.0%Entry 2
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Accumulation$24.96Entry 1
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
